patents

The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss
The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
Revlimid
patents
Flag link:
Ironwood, Allergan set to resolve LINZESS patent litigation with Mylan
Ironwood, Allergan set to resolve LINZESS patent litigation with Mylan
Pharmaceutical Business Review
Ironwood Pharmaceuticals
Mylan
patents
Linzess
Flag link:
Teva and Neos settle over Cotempla patent dispute
Teva and Neos settle over Cotempla patent dispute
Pharmaforum
Teva Pharmaceutical
Neos Therapeutics
generics
patents
ADHD
Cotempla XR-ODT
Flag link:
Democrats are suddenly eyeing a valuable pharma asset: its patents
Democrats are suddenly eyeing a valuable pharma asset: its patents
Stat
patents
drug pricing
Democrats
Flag link:
AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023
AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023
Fierce Pharma
AbbVie
biosimilars
Pfizer
Humira
patents
Flag link:
Pfizer wins blockbuster Lyrica patent extension to safeguard sales till June
Pfizer wins blockbuster Lyrica patent extension to safeguard sales till June
Fierce Pharma
Pfizer
Lyrica
patents
FDA
pediatric exclusivity
Flag link:
Johnson & Johnson shares swoon as pharma giant loses yet another fight to protect Zytiga sales
Johnson & Johnson shares swoon as pharma giant loses yet another fight to protect Zytiga sales
Fierce Pharma
JNJ
generics
Zytiga
Supreme Court
patents
Flag link:
Pfizer falls short in U.K. patent appeal for blockbuster Lyrica
Pfizer falls short in U.K. patent appeal for blockbuster Lyrica
Fierce Pharma
Pfizer
patents
UK
Lyrica
Flag link:
Boehringer Cites ‘Massive’ Number of Patents in Humira Biosimilar Suit
Boehringer Cites ‘Massive’ Number of Patents in Humira Biosimilar Suit
RAPS.org
Boehringer Ingelheim
AbbVie
Humira
patents
biosimilars
Flag link:
UC Regents issued 2nd CRISPR patent in U.S.
UC Regents issued 2nd CRISPR patent in U.S.
BioCentury
University of California
CRISPR
patents
Flag link:
Mylan's generic Copaxone wins in court, but market barriers remain
Mylan's generic Copaxone wins in court, but market barriers remain
Biopharma Dive
Teva Pharmaceutical
Copaxone
patents
MS
multiple sclerosis
Flag link:
In The Battle To Control Drug Costs, Old Patent Laws Get New Life
In The Battle To Control Drug Costs, Old Patent Laws Get New Life
Kaiser Health News
patents
drug pricing
Flag link:
Appeals court overturns patent board in Bard spat with AngioDynamics
Appeals court overturns patent board in Bard spat with AngioDynamics
Mass Device
devices
CR Bard
Becton Dickinson
AngioDynamics
patents
Flag link:
Drugmakers Play The Patent Game To Lock In Prices, Block Competitors
Drugmakers Play The Patent Game To Lock In Prices, Block Competitors
NPR
patents
Purdue Pharma
competition
opioids
Flag link:
New Patent Database to Help Governments Procure Medicines
New Patent Database to Help Governments Procure Medicines
RAPS.org
patents
Flag link:
Federal court rules Ampyra patents invalid, Acorda stock sinks 25%
Federal court rules Ampyra patents invalid, Acorda stock sinks 25%
Biopharma Dive
Acorda Therapeutics
MS
multiple sclerosis
AMPYRA
patents
Flag link:
Appeals court upholds CRISPR patents awarded to the Broad Institute
Appeals court upholds CRISPR patents awarded to the Broad Institute
Stat
CRISPR
patents
Broad Institute
University of California
Flag link:
[sponsored] Orange Book Companion® Adds New Features and Capabilities
[sponsored] Orange Book Companion® Adds New Features and Capabilities
CP Wire
patents
Hatch Waxman Act
FDA
exclusivity
Flag link:
[sponsored] Orange Book Companion® Adds New Features and Capabilities
patents
Hatch Waxman Act
FDA
exclusivity
Flag link:
Gleevec antitrust suits against Novartis, after failing initially, fall short again in appeals
Gleevec antitrust suits against Novartis, after failing initially, fall short again in appeals
Fierce Pharma
Novartis
Gleevec
patents
Flag link:

Pages